Diagnostic Values For Club Cell Secretory Protein (CC16) in Serum of Patients of Combined Pulmonary Fibrosis and Emphysema
Diagnostic Values For Club Cell Secretory Protein (CC16) in Serum of Patients of Combined Pulmonary Fibrosis and Emphysema
复制标题
DOI：
10.3109/15412555.2014.948994
复制
发表时间：
2015-08-01
影响因子：
2.2
通讯作者：
Kida, Kozui
中科院分区：
文献类型：
--
作者：
Kokuho, Nariaki;Ishii, Takeo;Kida, Kozui
肺纤维化合并肺气肿（CPFE）是一种认识不足的综合征，血清生物标志物的诊断应用是一个有吸引力的可能性。我们假设CC 16和/或TGF-β 1或与其他生物标志物的组合可用于诊断CPFE。根据胸部高分辨率计算机断层扫描的结果，将有呼吸道症状和吸烟史、伴或不伴慢性阻塞性肺疾病的患者分为以下三组：无肺气肿或纤维化的对照组、仅伴肺气肿的患者和符合CPFE诊断的患者。在病情稳定至少3个月的患者中测量CC 16、TGF-β 1、SP-D和KL-6的血清浓度。为了研究具有终生吸烟史的患者中肺纤维化的生物标志物的变化，对具有吸烟史的特发性肺纤维化（IPF）患者进行额外测量。前三组的平均年龄为68.0岁，而IPF组的平均年龄为71.8岁，各组分别包含36、115、27和10名个体。四组中CC 16的血清浓度分别为5.67 +/- 0.42、5.66 +/- 0.35、9.38 +/- 1.04和22.15 +/- 4.64 ng/ml，表明患有肺纤维化的那些患者具有显著更高的浓度。CC 16、SP-D和KL-6的联合使用结合放射学成像在诊断CPFE中提供了支持性诊断。我们的结论是，包括CC 16的生物标志物的组合可以提供有用的信息，以筛选和预测可能的诊断CPFE。
Combined pulmonary fibrosis and emphysema (CPFE) is an under-recognized syndrome for which the diagnostic use of serum biomarkers is an attractive possibility. We hypothesized that CC16 and/or TGF-beta 1 or combinations with other biomarkers are useful for diagnosing CPFE. Patients with respiratory symptoms and a smoking history, with or without chronic obstructive pulmonary disease, were divided into the following three groups according to findings of high-resolution computed tomography of the chest: controls without either emphysema or fibrosis, patients with emphysema alone, and patients compatible with the diagnosis of CPFE. Serum concentrations of CC16, TGF-beta 1, SP-D, and KL-6 were measured in patients whose condition was stable for at least 3 months. To investigate changes in biomarkers of lung fibrosis in patients with a life-long smoking history, additional measurements were performed on the patients with idiopathic pulmonary fibrosis (IPF) of smoking history. The mean age of the first three groups was 68.0 years, whereas that of the IPF group was 71.8 years, and the groups contained 36, 115, 27, and 10 individuals, respectively. The serum concentration of CC16 in the four groups was 5.67 +/- 0.42, 5.66 +/- 0.35, 9.38 +/- 1.04 and 22.15 +/- 4.64 ng/ml, respectively, indicating that those patients with lung fibrosis had a significantly higher concentration. The combined use of CC16, SP-D, and KL-6 provided supportive diagnosis in conjunction with radiological imaging in diagnosis of CPFE. We conclude that a combination of biomarkers including CC16 could provide useful information to screen and predict the possible diagnosis of CPFE.